Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on June 8, 2021. The filing documents the results of the Company's 2021 Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol "AGLE."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The following proposals were adopted at the Annual Meeting:
- Election of Directors: Two Class II directors were elected to three-year terms expiring at the 2024 Annual Meeting:
- Russell Cox: Received 28,983,201 votes "For" and 8,030,929 votes "Withheld." There were 6,184,697 broker non-votes.
- Ivana Magovcevic-Liebisch, Ph.D.: Received 28,852,314 votes "For" and 8,161,816 votes "Withheld." There were 6,184,697 broker non-votes.
- Ratification of Auditors: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
- Votes For: 43,195,403
- Votes Against: 2,210
- Votes Abstaining: 1,214
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote outcomes.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc., as the input metadata incorrectly referenced Spyre Therapeutics, Inc.
- Confirm the tenure of the newly elected directors (Russell Cox and Ivana Magovcevic-Liebisch) extends through the 2024 Annual Meeting.
- Note the significant number of broker non-votes (over 6 million) regarding the director elections, which may indicate specific proxy voting instructions or lack thereof.
- Review the Company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.